Evommune, Inc. (EVMN)
NYSE: EVMN · Real-Time Price · USD
22.87
-0.68 (-2.89%)
May 22, 2026, 4:00 PM EDT - Market closed
Evommune Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, Evommune stock has a consensus rating of "Strong Buy" and an average price target of $52.25. The average 1-year stock price forecast is 128.47% higher than the current stock price, while the lowest is $50 (+118.63%) and the highest is $55 (+140.49%).
Price Target: $52.25 (+128.47%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Evommune stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 2 | 2 | 3 | 3 | 3 |
| Buy | 5 | 6 | 6 | 6 | 7 | 7 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 8 | 8 | 9 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Maintains $54 → $55 | Buy | Maintains | $54 → $55 | +140.49% | May 11, 2026 |
| RBC Capital | RBC Capital | Buy Reiterates $48 | Buy | Reiterates | $48 | +109.88% | Apr 10, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $65 → $50 | Strong Buy | Maintains | $65 → $50 | +118.63% | Mar 18, 2026 |
| Clear Street | Clear Street | Strong Buy Initiates $53 | Strong Buy | Initiates | $53 | +131.74% | Mar 18, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $35 → $65 | Strong Buy | Maintains | $35 → $65 | +184.22% | Feb 10, 2026 |
Financial Forecast
Revenue This Year
n/a
from 13.00M
Revenue Next Year
n/a
EPS This Year
-2.80
from -11.22
EPS Next Year
-3.48
from -2.80
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.18 | -2.60 | ||||||
| Avg | -2.80 | -3.48 | ||||||
| Low | -3.23 | -4.73 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.